A New Guardian of Ferroptosis: Farnesoid X Receptor

Featured Publication Molecular Targets and Therapeutics SAT

Understanding ferroptosis is essential for addressing degenerative diseases and certain cancers. Researchers, led by Dr. Kamyar Hadian from Helmholtz Munich, revealed that the Farnesoid X Receptor (FXR), activated by bile acids, serves as a master regulator of ferroptosis, suggesting potential therapeutic avenues for disease treatment.

Cell death is very important for the proper functioning of almost all multicellular organisms. Cell death helps maintain tissue homeostasis by eliminating damaged or dysfunctional cells. There are a number of different cell death programs that occur in a regulated manner. One of them is ferroptosis, which involves iron-dependent oxidative damage to cellular lipids, which are essential components of cell membranes. This leads to the breakdown of cell membranes and finally cell death. Ferroptosis is present in a number of degenerative diseases including neurodegeneration, acute kidney and liver injury, and many others. In addition, several cancers have been shown to be susceptible to ferroptotic cell death. Therefore, understanding the molecular mechanisms that regulate ferroptosis is essential to identify specific targets for therapeutic intervention. The last decade of ferroptosis research has uncovered several mechanisms that induce or inhibit ferroptosis. Yet, many regulatory details remain to be discovered.

Farnesoid X Receptor Activation by Bile Acids Prevents Ferroptotic Cell Death

A team of researchers led by Dr. Kamyar Hadian from the Research Unit Signaling and Translation at Helmholtz Munich performed a chemical genetics screen to identify novel regulators of ferroptosis. This means, that the scientists exposed cells to thousands of diverse compounds with known mode of action and subsequently assessed cell viability. This approach was employed to elucidate the pathways and regulators associated with ferroptosis. They discovered that the nuclear receptor Farnesoid X Receptor (FXR) is a potent inhibitor of lipid peroxidation and ferroptosis. The FXR is mainly expressed in the liver, kidney, and small intestine, and is activated by bile acids. This study, published in Nature Communications, demonstrates that the FXR is a master regulator of ferroptosis by upregulating the transcription of essential ferroptosis gatekeepers, thereby inhibiting lipid peroxidation and ferroptosis. Hence, the activation of FXR by bile acids or specific small molecules effectively rescued cells from ferroptotic cell death.

These findings suggest that organs and tissues that are generally at higher exposure to toxins or drug metabolites have upregulated FXR as a protective measure against ferroptotic cell death. Specific compounds that activate FXR will be evaluated in future studies as novel molecules in the treatment of degenerative diseases such as acute kidney or liver injury to prevent cell death by ferroptosis. Moreover, this study provides an unexpected novel function for bile acids as suppressors of lipid peroxidation and ferroptosis.

 

Original publication

Tschuck et. al (2023): Farnesoid X Receptor activation by bile acids suppresses lipid peroxidation and ferroptosis. Nature Communications. DOI: https://doi.org/10.1038/s41467-023-42702-8 

About the scientists

Juliane Tschuck, doctoral researcher at the Research Unit Signaling and Translation at Helmholtz Munich

Dr. Kamyar Hadian, Deputy Director of the Research Unit Signaling and Translation at Helmholtz Munich

Related news

HMGU_Icon_Molecular_Targets

Featured Publication, MCD,

Precursor of Cholesterol Protects Cells From Ferroptosis

A precursor of cholesterol, previously categorised as harmful, can protect cancer cells from cell death. This finding, published in Nature, opens new doors for cancer research.

Superimposed human FSP1 structure with its cofactors, FAD, NADH, and CoQ5

New Research Findings, Molecular Targets and Therapeutics, MCD,

A Rising Star: Inducing Ferroptosis with Innovative Compounds for Cancer Therapy

A team of researchers led by Dr. Marcus Conrad from Helmholtz Munich discovered a novel anti-cancer drug, called viFSP1, which sensitizes both murine and human cancer cells to cell death through ferroptosis. Ferroptosis is defined by the…

Dr. Kamyar Hadian and Prof. Dr. Ulrike Protzer

Awards & Grants, Molecular Targets and Therapeutics, SAT, VIRO,

Double Triumph for Helmholtz Munich: Two Researchers Honored with m4 Award from BioM

Prof. Ulrike Protzer and Dr. Kamyar Hadian and their teams from Helmholtz Munich received the prestigious Bavarian m4 Award, a recognition of their exceptional contributions to the advancement of future medicine and two different groundbreaking…

DHODH inhibitor brequinar

New Research Findings, MCD,

Potentiating Cancer Vulnerability to Ferroptosis: Off-Targeting Effects of DHODH Inhibitors

A research team at Helmholtz Munich revealed a specific mechanism that is able to promote cell death in cancer cells by pharmacological targeting of a ferroptosis surveillance system. Ferroptosis is a form of regulated oxidative cell death and has…

FSP1 condensates in green induced by icFSP1 surrounding a blue nucleus

New Research Findings, MCD,

New Approach in Cancer Therapy With Innovative Mechanism-of-Action for Ferroptosis Induction

A team of researchers led by Dr. Marcus Conrad from Helmholtz Munich discovered a novel anti-cancer drug, called icFSP1, which sensitizes cancer cells to ferroptosis. Ferroptosis is characterized by the iron-dependent oxidative destruction of…